Is a platelet suntan the answer?

Transfusion

Volumn 59, Issue 4, 2019, Pages 1163-1165

  Wagner, Stephen J ^a   Getz, Todd M ^a  

^a AMERICAN RED CROSS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EDITORIAL; ESCHERICHIA COLI; NONHUMAN; PHOTOCHEMISTRY; STREPTOCOCCUS PYOGENES; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE FUNCTION; THROMBOCYTE LIFESPAN; THROMBOCYTE METABOLISM; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION; ULTRAVIOLET C RADIATION; BACTERIUM; SKIN; SUNTAN;

BACTERIA; BLOOD PLATELETS; SKIN; SUNTAN;

EID: 85063979520     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.15196     Document Type: Editorial

References (19)

1. US Food and Drug Administration. Bacterial risk control strategies for blood collection establishments and transfusion services to enhance the safety and availability of platelets for transfusion: draft guidance for industry. 2018. [cited 2019 January 18]. Available from: https://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM627407.pdf
2. Lin L, Dikeman R, Molini B, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44:1496-504.
3. Keil SD, Hovenga N, Gilmour D, et al. Treatment of platelet products with riboflavin and UV light: effectiveness against high titer bacterial contamination. J Vis Exp 2015;102:e52820.
4. Benjamin RJ, Wagner SJ. Bacterial pathogen reduction requires validation under conditions of intended use. Transfusion 2015;55:2060-3.
5. Wagner SJ, Benjamin RJ, Hapip CA, et al. Investigation of bacterial inactivation in apheresis platelets with 24 or 30 hours between inoculation and inactivation. Vox Sang 2016;111:226-34.
6. Goodrich RP, Gilmour D, Hovenga N, et al. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns. Transfusion 2009;49:1205-16.
7. Magron A, Laugier J, Provost P, et al. Pathogen reduction technologies: the pros and cons for platelet transfusion. Platelets 2018;29:2-8.
8. Bashir S, Cookson P, Wiltshire M, et al. Pathogen inactivation of platelets using ultraviolet C light: effect on in vitro function and recovery and survival of platelets. Transfusion 2013;53:990-1000.
9. Snyder E, Raife T, Lin L, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44:1732-40.
10. AuBuchon JP, Herschel L, Roger J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45:1335-41.
11. Mohr H, Gravemann U, Bayer A, et al. Sterilization of platelet concentrates at production scale by irradiation with short-wave ultraviolet light. Transfusion 2009;49:1956-63.
12. Mohr H, Steil L, Gravemann U, et al. A novel approach to pathogen reduction in platelet concentrates using short-wave ultraviolet light. Transfusion 2009;49:2612-24.
13. Johnson L, Hyland R, Tan S, et al. In vitro quality of platelets with low plasma carryover treated with ultraviolet C light for pathogen inactivation. Transfus Med Hemother 2016;43:190-7.
14. Janetzko K, Hinz K, Marschner S, et al. Evaluation of different preparation procedures of pathogen reduction technology(Mirasol®)-treated platelets collected by plateletpheresis. Transfus Med Hemother 2009;36:309-15.
15. Janetzko K, Lin L, Eichler H, et al. Implementation of the INTERCEPT Blood System for Platelets into routine blood bank manufacturing procedures: evaluation of apheresis platelets. Vox Sang 2004;86:239-45.
16. Sandgren P, Tolksdorf F, Struff WG, et al. In vitro effects on platelets irradiated with short-wave ultraviolet light without any additional photoactive reagent using the THERAFLEX UV-Platelets method. Vox Sang 2011;101:35-43.
17. Picker SM, Steisel A, Gathof BS. Effects of Mirasol PRT treatment on storage lesion development in plasma-stored apheresis-derived platelets compared to untreated and irradiated units. Transfusion 2008;48:1685-92.
18. Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85.
19. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101:2426-33.